Cardiovascular safety of non-steroidal anti-inflammatory drugs in chronic inflammatory rheumatic diseases


Cite item

Full Text

Abstract

Rheumatic diseases (RD), such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, vasculitis, gout are associated with increase in cardiovascular morbidity and mortality. The main causes of increased cardiovascular risk are inflammatory heart and vascular lesions, accelerated progression of atherosclerosis and side effects of drug therapy. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in clinical practice and are on the list of the most prescribed medications. It is known that NSAIDs have a negative effect on the cardiovascular system (CVS). However NSAIDs may decrease the intensity of inflammation, which is an independent risk risk factor for CVS pathology. Therefore in patients with RD it is theoretically possible to reduce the severity of cardiovascular side effects when using NSAIDs. The article discusses the issues of NSAID’s cardiovascular safety, the molecular mechanisms underlying the negative effect of them on CVS, critically evaluated the results of main studies concerning the cardiovascular safety of NSAIDs in chronic inflammatory diseases.

About the authors

B V Zavodovsky

A.B. Zborovsky Research Institute of Clinical and Experimental Rheumatology

Email: pebma@mail.ru
д.м.н., проф., зав. лаб. методов лечения и профилактики заболеваний суставов Volgograd, Russia

L E Sivordova

A.B. Zborovsky Research Institute of Clinical and Experimental Rheumatology

Email: seeword@mail.ru
к.м.н., в.н.с. лаб. методов лечения и профилактики заболеваний суставов Volgograd, Russia

References

  1. Заводовский Б.В. Влияние нестероидных противовоспалительных препаратов на сердечно - сосудистую систему. Кардиология. 2015;55(7):84-88
  2. Каратеев А.Е., Новикова Д.С., Насонов Е.Л. Новые данные, касающиеся безопасности нестероидных противовоспалительных препаратов: представление о «класс - специфическом» высоком кардиоваскулярном риске селективных ингибиторов циклооксигеназы 2 устарело. Научно - практическая ревматология. 2017;55(2):218-223
  3. Peters M, Symmons D, Mccarey D, Dijkmans B, Nicola P, Kvien T, et al. EULAR evidence - based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-331. doi: 10.1136/ard.2009.113696
  4. Peters M, van Halm V, Voskuyl A, Smulders Y, Boers M, Lems W, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A Prospective Study. Arthritis Rheum. 2009;61:1571-1579. doi: 10.1002/art.24836
  5. Nicola P, Maradit-Kremers H, Roger V, Jacobsen S, Crowson C, Ballman K, et al. The risk of congestive heart failure in rheumatoid arthritis: a population - based study over 46 years. Arthritis Rheum. 2005;52:412-420. doi: 10.1002/art.20855
  6. Середавкина Н.В., Смирнов А.В., Дыдыкина И.С., Решетняк Т.М. Глюкокортикоиды в лечении системной красной волчанки: положительные и отрицательные стороны. Клиницист. 2014;(1):63-70
  7. Esdaile J.M, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337. PMID: 11665973
  8. Schoenfeld S.R, Kasturi S, Costenbader K.H. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43:77-95. doi: 10.1016/ j.semarthrit.2012.12.002
  9. Насонов Е.Л., Мазуров В.И., Лила А.М., Эрдес Ш.Ф., Каратеев Д.Е., Верткин А.Л., Зырянов С.К., Дубиков А.И., Фролов М.Ю., Обухова О.В. Резолюция Совещания Экспертов по теме: «Вопросы повышения доступности инновационных методов для пациентов со спондилоартритами». Научно - практическая ревматология. 2017;55(4):457-460. doi: 10.14412/1995-4484-2017-457-459
  10. Bremander A, Petersson I.F, Bergman S, Englund M. Population - based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res. 2011;63:550-556. doi: 10.1002/acr.20408 PMID: 21452267
  11. Szabo S.M, Levy A.R, Rao S.R, Kirbach S.E, Lacaille D, Cifaldi M, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population - based study. Arthritis Rheum. 2011;63:3294-3304. doi: 10.1002/art.30581
  12. Gabriel S.E. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121:S9-S14. doi: 10.1016/j.amjmed.2008. 06.011
  13. Goodson N.J, Wiles N.J, Lunt M, Barrett E.M, Silman A.J, Symmons D.P. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010-2019. doi: 10.1002/art.10419
  14. Wallberg-Jonsson S, Johansson H, Ohman M.L, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999;26:2562-2571. PMID: 10606363.
  15. Павлова А.Б., Ахвердян Ю.Р., Симакова Е.С. и др. Определение адипонектина у работников промышленных предприятий с воспалительными заболеваниями суставов. Медицина труда и промышленная экология. 2013;(1):38-41.
  16. Hollan I, Meroni P.L, Ahearn J.M, Cohen Tervaert J.W, Curran S, Goodyear C.S, Hestad K.A, Kahaleh B, Riggio M, Shields K, Wasko M.C. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013;12:1004-1015. doi: 10.1016/j.autrev.2013.03.013
  17. Симакова Е.С., Заводовский Б.В., Сивордова Л.Е., Полякова Ю.В., Кравцов В.И., Зборовский А.Б. Прогностическое значение нарушений липидного обмена в патогенезе остеоартроза. Вестник Российской военно - медицинской академии. 2013;2(42):29-32.
  18. Libby P, Ridker P.M, Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325. doi: 10.1038/nature10146
  19. Stevens R, Douglas K, Saratzis A, Kitas G. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med. 2005;7:1-24. doi: 10.1017/S1462399405009154
  20. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51:v3-11. doi: 10.1093/rheumatology/kes113
  21. Liao K, Solomon D. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:45-52. doi: 10.3899/jrheum.090188
  22. Mavrogeni S, Spargias K, Markussis V, Kolovou G, Demerouti E, Papadopoulou E, et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. Inflamm Allergy Drug Targets. 2009;8:390-397. PMID: 20025587.
  23. Sandoo A, Kitas G, Carroll D, Veldhuijzen Van Zanten J. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross - sectional and longitudinal study. Arthritis Res Ther. 2012;14:R117. doi: 10.1186/ar3847
  24. Драпкина О.М., Ашихмин Я.И. Воздействие нестероидных противовоспалительных средств и селективных ингибиторов циклооксигеназы-2 на сердечно - сосудистую систему. Российские медицинские вести. 2007;12(3):62-66.
  25. Сивордова Л.Е., Заводовский Б.В., Полякова Ю.В., Ахвердян Ю.Р. Доказательства целесообразности применения эторикоксиба в терапии остеоартроза у пациентов старших возрастных групп. Успехи геронтологии. 2016;29(2):286-290.
  26. Насонов Е.Л., Насонова В.А., редакторы. Ревматология: национальное руководство. Москва: ГЭОТАР-Медиа; 2008. 720 с.
  27. Заводовский Б.В., Сивордова Л.Е., Полякова Ю.В., Ахвердян Ю.Р., Кузнецова М.И., Зборовская И.А. Сравнительная эффективность и безопасность эторикоксиба и мелоксикама в лечении больных гонартрозом. Терапевтический архив. 2016;88:78-81. doi: 10.17116/terarkh 2016881278-81
  28. Насонов Е.Л., Ивашкин В.Т., Яхно Н.Н., Мартынов А.И., Арутюнов Г.П., Каратеев А.Е., Алексеева Л.И., Чичасова Н.В., Евсеев М.А., Кукушкин М.Л., Лила А.М., Ребров А.П. и др. Проект Национальных клинических рекомендаций (Основные положения) Ассоциации ревматологов России, Российской гастроэнтерологической Ассоциации, Российского общества по изучению боли «Рациональное использование нестероидных противовоспалительных препаратов». Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):69-75. doi: 10.22416/1382-4376-2017-27-5-69-75
  29. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non - steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case - control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857
  30. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Argas R, Davis B, Day R, Ferraz M.B, Hawkey C.J, Hochberg M.C, Kvien T.K, Schnitzer T.J; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520-1528. doi: 10.1056/NEJM 200011233 432103
  31. Nussmeier N.A, Whelton A.A, Brown M.T, Langford R.M, Hoeft A, Parlow J.L, Boyce S.W, Verburg K.M. Complications of the COX-2 inhibitors parecoxiband valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081-1091. doi: 10.1056/NEJMoa050330
  32. Solomon S.D, Mc Murray J.J, Pfeffer M.A, Wittes J, Fowler R, Finn P, Anderson W.F, Zauber A, Hawk E, Bertagnolli M. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-1080. doi: 10.1056/NEJMoa050405
  33. Bresalier R.S, Sandler R.S, Quan H, Bolognese J.A, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam M.A, Baron J.A. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102. doi: 10.1056/NEJMoa050493
  34. Back M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation - wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012;33:1928-1933. doi: 10.1093/eurheartj/ ehr421
  35. Kearney P.M, Baigent C, Godwin J, Halls H, Emberson J.R, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional nonsteroidal anti - inflammatory drugs increase the risk of atherothrombosis? Meta - analysis of randomised trials. BMJ. 2006;332(7553):1302-1308. doi: 10.1136/bmj.332.7553.1302
  36. Cannon C.P, Curtis S.P, Fitz Gerald G.A, Krum H, Kaur A, Bolognese J.A, Reicin A.S, Bombardier C, Weinblatt M.E, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long - term (MEDAL programme: a randomized comparison. Lancet. 2006;368(9549):1771-1781. doi: 10.1016/S0140-6736(06) 69666-9
  37. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti - Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1(7):e33. doi: 10.1371/journal.pctr.0010033
  38. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron J.A, Bombardier C, Cannon C, Farkouh M.E, Fitz Gerald G.A, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland L.E, Kearney P.M, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer T.J, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non - steroidal anti - inflammatory drugs: meta - analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779. doi: 10.1016/S0140-6736(13)60900-9
  39. Hirayama A, Tanahashi N, Daida H, Ishiguro N, Chachin M, Siguoka T. Assessing the Cardiovascular Risk Between Celecoxib and Nonselective Nonsteroidal Antiinflammatory Drugs in Patients With Rheumatoid Arthritis and Osteoarthritis. Circ J. 2014;78(1):194-205. doi: 10.1253/circj.CJ-12-1573
  40. Rahme E, Watson D.J, Kong S.X, Toubouti Y, Le Lorier J. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2007;16(5):493-503. doi: 10.1002/pds.1339
  41. Schjerning Olsen A.M, Fosbol E.L, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen P.R, Torp-Pedersen C, Gislason G.H. Duration of treatment with nonsteroidal anti - inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-2235. doi: 10.1161/CIRCULATIONAHA.110.004671
  42. Sudano I, Flammer A.J, Roas S, Enseleit F, Noll G, Ruschitzka F. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep. 2012;14(4):304-309. doi: 10.1007/s11906-012-0274-7
  43. White W.B, Schnitzer T.J, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol. 2009;104(6):840-845. doi: 10.1016/ j.amjcard.2009.05.014
  44. Dallob A, Hawkey C.J, Greenberg H.M, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K. Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. J Clin Pharmacol. 2003;43(6):573-585. doi: 10.1177/ 0091270003253703
  45. Kirkby N.S, Lundberg M.H, Harrington L.S, Leadbeater P.D, Milne G.L, Potter C.M, Al-Yamani M, Adeyemi O, Warner T.D, Mitchell J.A. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA. 2012;109(43):17597-17602. doi: 10.1073/pnas. 1209192109
  46. St Germaine C.G, Bogaty P, Boyer L, Hanley J, Engert J.C, Brophy J.M. Genetic polymorphisms and the cardiovascular risk of non - steroidal anti - inflammatory drugs. Am J Cardiol. 2010;105(12):1740-1745. doi: 10.1016/j.amjcard.2010.01.352
  47. Shapiro M.S. An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated Puzzle? Mol Pharmacol. 2009;76:942-945. doi: 10.1124/ mol.109.059683
  48. Gunter B.R, Butler K.A, Wallace R.L, Smith S.M, Harirforoosh S. Non - steroidal anti - inflammatory drug - induced cardiovascular adverse events: a meta - analysis. J Clin Pharm Ther. 2017;42:27-38. doi: 10.1111/jcpt.12484
  49. Agca R, Heslinga S.C, Rollefstad S, Heslinga M, Mc Innes I.B, Peters M.J.L, Kvien T.K, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen T.R, Jacobsson L, de Vlam K, Gonzalez-Gay M.A, Semb A.G, Kitas G.D, Smulders Y.M, Szekanecz Z, Sattar N, Symmons D.P.M, Nurmohamed M.T. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016;0:1-12. doi: 10.1136/annrheumdis-2016-209775
  50. Horbach S.J, Lopes R.D, da C Guaragna J.C, Martini F, Mehta R.H, Petracco J.B, Bodanese L.C, Filho A.C, Cirenza C, de Paola A.A. NAFARM Investigators. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med. 2011;124(11):1036-1042. doi: 10.1016/j.amjmed.2011.07.026
  51. Goodson N.J, Brookhart A.M, Symmons D.P, Silman A.J, Solomon D.H. Non - steroidal anti - inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68(3):367-372. doi: 10.1136/ ard.2007.076760
  52. Lindhardsen J, Gislason G.H, Jacobsen S, Ahlehoff O, Olsen A.M.S, Madsen O.R, Torp-Pedersen C, Hansen P.R. Non - steroidal anti - inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014;73(8):1515-1521. doi: 10.1136/annrheumdis-2012-203137
  53. De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S. Cardiovascular risk associated with celecoxib or etoricoxib: a meta - analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol. 2014;62(6):437-448. PubMed ID 25029569. http://www.minervamedica.it/en/journals/minerva-cardioangiologica/article.php?cod=R05 Y9999N00A 140053
  54. Mac Donald Т., Hawkey С, Ford I, et al. On behalf of SCOT investigators (The Standard Care versus Celecoxib Outcome Trial). BMJ Open. 2013;3:e002295. https://clinicaltrials.gov/ct2/show/NCT00447759
  55. Nissen S.E, Yeomans N.D, Solomon D.H, Luscher T.F, et al. for the PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New Engl J Med. 2016. doi: 10.1056/NEJMoa1611593
  56. Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landewé R, van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of non - pharmacological and non - biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3:e000397. doi: 10.1136/rmdopen-2016-000397
  57. Tsai W-C, Ou T-T, Yen J-H, Wu C-C, Tung Y-C. Long-Term Frequent Use of Non-Steroidal Anti-Inflammatory Drugs Might Protect Patients with Ankylosing Spondylitis from Cardiovascular Diseases: A Nationwide Case-Control Study. PLoS ONE. 2015;10(5):e0126347. doi: 10.1371/journal.pone.0126347
  58. Ogdie A, Yu Y, Haynes K, Love T.J, et al. Risk of Major Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A population - based cohort study. Ann Rheum Dis. 2015 Feb;74(2):326-332. doi: 10.1136/annrheumdis-2014-205675
  59. Kristensen L.E, Jakobsen A.K, Askling J, et al. Safety of etoricoxib, celecoxib, and nonselective nonsteroidal antiinflammatory drugs in ankylosing spondylitis and other spondyloarthritis patients: a Swedish National Population - based Cohort Study. Arthritis Care Res (Hoboken). 2015;67:1137-1149. doi: 10.1002 / acr.22555
  60. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger P, et al. Cardiovascular safety of non - steroidal anti - inflammatory drugs: network meta - analysis. BMJ. 2011;342:c7086.
  61. Roubille C, Richer V, Starnino T, Mc Court C, Mc Farlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non - steroidal anti - inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta - analysis. Ann Rheum Dis. 2015;74:480-489. doi: 10.1136/annrheumdis-2014-206624
  62. Essers I, Stolwijk C, Boonen A, De Bruin M.L, Bazelier M.T, de Vries F, van Tubergen A. Ankylosing spondylitis and risk of ischaemic heart disease: a population - based cohort study. Ann Rheum Dis. 2016;75:203-209. doi: 10.1136 / annrheumdis-2014-206147
  63. Zhang Y.P, Gong Y, Zeng Q.Y, Hou Z.D, Xiao Z.Y. A long - term, observational cohort study on the safety of low - dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index. BMJ Open. 2015;5:e006957. doi: 10.1136/bmjopen-2014-006957
  64. Tzu-Chieh Lin, Pharm B, Solomon D.H, Tedeschi S.K, Yoshida K, Yea-Huei Kao Yang. Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis. Am Heart Assoc. 2017;6:006874. doi: 10.1161/JAHA.117.006874

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies